Lanean...
Exploiting receptor tyrosine kinase co-activation for cancer therapy
Studies over the past decade have shown that Receptor Tyrosine Kinase (RTK) co-activation is prevalent in many cancer types. Compelling data demonstrates that cancers are likely to have evolved RTK co-activation as a generic means for driving tumour growth and providing a buffering system to limit t...
Gorde:
| Argitaratua izan da: | Drug Discov Today |
|---|---|
| Egile Nagusiak: | , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2016
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5346155/ https://ncbi.nlm.nih.gov/pubmed/27452454 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.drudis.2016.07.010 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|